Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIOPEN High-Risk Neuroblastoma Study 2
2019-001068-31Phase 3Active
- Sponsor
- Gustave Roussy
- Start
- Jun 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of busulfan, melphalan, thiotepa, carboplatin, cisplatin and 8 more in neuroblastoma (4 arms), sponsored by Gustave Roussy. Primary endpoint: 3-year event-free survival. Started Jun 2019; status: active.
02
Drugs
busulfanmelphalanthiotepacarboplatincisplatin
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on 2019-001068-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001068-31.